7B9U

Structural Analysis and Development of Notum Fragment Screening Hits.

(2022) ACS Chem Neurosci 13: 2060-2077

• PubMed: 35731924 Search on PubMedSearch on PubMed Central
• DOI: https://doi.org/10.1021/acschemneuro.2c00325
• Primary Citation of Related Structures:  
  7B4X, 7B84, 7B86, 7B87, 7B89, 7B8C, 7B8D, 7B8F, 7B8G, 7B8J, 7B8K, 7B8L, 7B8M, 7B8N, 7B8O, 7B8U, 7B8X, 7B8Y, 7B8Z, 7B98, 7B99, 7B9D, 7B9I, 7B9N, 7B9U, 7BA1, 7BAC, 7BAP, 7BC8, 7BC9, 7BCC, 7BCD, 7BCF, 7BCH, 7BCI, 7BCK, 7BCL, 7BD2, 7BD3, 7BD4, 7BD5, 7BD6, 7BD8, 7BD9, 7BDA, 7BDB, 7BDC, 7BDD, 7BDF, 7BDG


• PubMed Abstract: 
  

  The Wnt signaling suppressor Notum is a promising target for osteoporosis, Alzheimer's disease, and colorectal cancers. To develop novel Notum inhibitors, we used an X-ray crystallographic fragment screen with the Diamond-SGC Poised Library (DSPL) and identified 59 fragment hits from the analysis of 768 data sets. Fifty-eight of the hits were found bound at the enzyme catalytic pocket with potencies ranging from 0.5 to >1000 μM. Analysis of the fragments' diverse binding modes, enzymatic inhibitory activities, and chemical properties led to the selection of six hits for optimization, and five of these resulted in improved Notum inhibitory potencies. One hit, 1 - phenyl-1,2,3-triazole 7 , and its related cluster members, have shown promising lead-like properties. These became the focus of our fragment development activities, resulting in compound 7d with IC ₅₀ 0.0067 μM. The large number of Notum fragment structures and their initial optimization provided an important basis for further Notum inhibitor development.

   View More

---

Organizational Affiliation: 

Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Roosevelt Drive, Oxford OX3 7BN, U.K.